posted on 2020-03-26, 20:45authored byZijian Fang, Shiqian Chen, Philip Pickford, Johannes Broichhagen, David J. Hodson, Ivan R. Corrêa, Sunil Kumar, Frederik Görlitz, Chris Dunsby, Paul M. W. French, Guy A. Rutter, Tricia Tan, Stephen R. Bloom, Alejandra Tomas, Ben Jones
Signal
bias and membrane trafficking have recently emerged as important
considerations in the therapeutic targeting of the glucagon-like peptide-1
receptor (GLP-1R) in type 2 diabetes and obesity. In the present study,
we have evaluated a peptide series with varying sequence homology
between native GLP-1 and exendin-4, the archetypal ligands on which
approved GLP-1R agonists are based. We find notable differences in
agonist-mediated cyclic AMP signaling, recruitment of β-arrestins,
endocytosis, and recycling, dependent both on the introduction of
a His → Phe switch at position 1 and the specific midpeptide
helical regions and C-termini of the two agonists. These observations
were linked to insulin secretion in a beta cell model and provide
insights into how ligand factors influence GLP-1R function at the
cellular level.